Meeting
2018 ASCO Annual Meeting
Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.
Authors
Stefan K. Barta
Fox Chase Cancer Center, Philadelphia, PA
Stefan K. Barta , Drew W. Rasco , Andy I. Chen , Stephanie Elkins , Michael Wang , Louis J. Denis , Sarper Toker , Helen Usansky , Sanjeeva Reddy , Niranjan Sathyanarayana Rao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Other Leukemia, Myelodysplastic Syndromes, and Allotransplant
Clinical Trial Registration Number
NCT02440685
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS7084)
DOI
10.1200/JCO.2018.36.15_suppl.TPS7084
Abstract #
TPS7084
Poster Bd #
138b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
First Author: Paul A. Hamlin
Poster
2015 ASCO Annual Meeting
Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.
First Author: James J. Harding
Poster
2024 ASCO Annual Meeting
A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
First Author: John C. Byrd
Poster
2022 ASCO Annual Meeting
Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.
First Author: Ryan C Lynch